financetom
Business
financetom
/
Business
/
SoftBank, OpenAI unveil Japan AI joint venture
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SoftBank, OpenAI unveil Japan AI joint venture
Feb 2, 2025 10:50 PM

TOKYO (Reuters) -SoftBank Group CEO Masayoshi Son said on Monday he has agreed with OpenAI CEO Sam Altman to set up a joint venture in Japan to offer artificial intelligence services to corporate customers.

The Japanese investment giant will also pay $3 billion annually to use OpenAI's technology across SoftBank group companies.

The joint venture, SB OpenAI Japan, will be owned by OpenAI and a company established by SoftBank and its domestic telecoms arm.

Son is moving to deepen his exposure to OpenAI, with SoftBank looking at investing $15 billion to $25 billion in the company, Reuters reported last week.

SoftBank is also committing $15 billion to Stargate, a joint venture with OpenAI and Oracle to build AI capacity in the U.S., Reuters has reported.

The Stargate launch last month saw Son make his second appearance with Donald Trump since his election as president in November.

Son's backing for OpenAI reflects his reemergence as an investment force after a period of retrenchment sparked by the falling value of SoftBank's tech portfolio and a series of high profile stumbles.

He has a long history of partnering with tech firms in the U.S., with SoftBank bringing the iPhone to Japan in 2008.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dianthus Therapeutics Says Claseprubart Showed Meaningful Improvements in Myasthenia Gravis Patients
Dianthus Therapeutics Says Claseprubart Showed Meaningful Improvements in Myasthenia Gravis Patients
Sep 8, 2025
08:29 AM EDT, 09/08/2025 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said Monday claseprubart demonstrated statistically significant and clinically meaningful improvements in a phase 2 study of adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The therapy improved daily living and muscle strength scores as early as the first week and maintained benefits through week 13, the company...
Netskope Seeks to Raise Up to $812.6 million in IPO
Netskope Seeks to Raise Up to $812.6 million in IPO
Sep 8, 2025
08:26 AM EDT, 09/08/2025 (MT Newswires) -- Netskope expects to raise between $717 million and $812.6 million in its initial public offering, according to a Monday filing with the US Securities and Exchange Commission. The cloud-security provider said it will offer 47.8 million class A common shares, expected to be priced between $15 and $17 per share. Underwriters have been...
Marqeta Announces Appointment of Mike Milotich as CEO
Marqeta Announces Appointment of Mike Milotich as CEO
Sep 8, 2025
08:28 AM EDT, 09/08/2025 (MT Newswires) -- Marqeta ( MQ ) said Monday it has appointed Mike Milotich as chief executive officer, effective today. The company said Milotich has served as interim CEO since February, in addition to his role of chief financial officer. He will continue to serve as CFO until a successor has been identified, the company said....
Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer
Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer
Sep 8, 2025
08:28 AM EDT, 09/08/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Monday that data from three metastatic colorectal cancer, or mCRC studies for its immunotherapy pelareorep showed consistent efficacy signals, immune activation, and survival outcomes that exceeded benchmarks in multiple treatment settings. The REO 022 trial, which evaluates pelareorep in combination with Folfiri and bevacizumab in platinum refractory...
Copyright 2023-2026 - www.financetom.com All Rights Reserved